TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33383447

Group type: EXPERIMENTAL
Intervention: SSS07 (5, 15, 30, 50, 75, and 100 mg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: SSS07 (lower doses)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: SSS07 (100 mg)
Number of subjects: 71
Study: 32901235

Group type: EXPERIMENTAL
Intervention: Paracetamol (15 mg/kg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 102
Study: 34049916

Group type: EXPERIMENTAL
Intervention: Daily Mile schools (intervention group)
Number of subjects: 3533

Group type: COMPARATOR
Intervention: Non-Daily Mile schools (control group)
Number of subjects: 3533
Study: 32068436

Group type: EXPERIMENTAL
Intervention: SAR341402 (SAR‐Asp)
Number of subjects: 597

Group type: COMPARATOR
Intervention: NN‐Asp (originator insulin aspart)
Number of subjects: 597
Study: 35778368

Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy (LiSWT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 51
Study: 34446156

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg once daily
Number of subjects: 5522
Study: 35118992

Group type: EXPERIMENTAL
Intervention: Urethral plate tubularization
Number of subjects: 43

Group type: COMPARATOR
Intervention: Mathieu technique
Number of subjects: 43
Study: 32061505

Group type: EXPERIMENTAL
Intervention: Empiric broad-spectrum antibiotic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial oral or parenteral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shorter courses of therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic time out protocol
Number of subjects: 0
Study: 34986194

Group type: EXPERIMENTAL
Intervention: Dietary intervention of minimal and unprocessed foods for three to six months, including five times per week green vegetables, three times per week beef, daily 200-300 mL whole cow's milk (3.4% fat), and whole dairy butter (80% fat) on each slice of bread.
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group continued their usual dietary habits.
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Dietary intervention of minimal and unprocessed foods for three to six months.
Number of subjects: 267
Study: 33323442

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3 g/day of n-3 polyunsaturated fatty acids)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 128
Study: 34339988

Group type: EXPERIMENTAL
Intervention: Ozone exposure (200 ppb)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Clean air exposure
Number of subjects: 22
Study: 33615404

Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle ACL reconstruction (DB)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Anatomic single-bundle ACL reconstruction (SB)
Number of subjects: 57
Study: 32444670

Group type: EXPERIMENTAL
Intervention: Cervical dilatation at the 3rd, 5th, and 8th week after LEEP (Intervention Group A)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Cervical dilatation at the 4th, 8th, and 12th week after LEEP (Intervention Group B)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control group (without any intervention)
Number of subjects: 404
Study: 34560806

Group type: EXPERIMENTAL
Intervention: Reduced-dose alteplase regimen
Number of subjects: 650

Group type: COMPARATOR
Intervention: Standard heparin anticoagulation
Number of subjects: 650
Study: 33538113

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg subcutaneously every 8 weeks
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg subcutaneously every 8 weeks
Number of subjects: 3021

Group type: COMPARATOR
Intervention: NSAIDs (oral naproxen, celecoxib, or diclofenac twice daily)
Number of subjects: 3021
Study: 33636453

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 396

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 396
Study: 32202075

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 1377

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 1377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1377
Study: 35836281

Group type: EXPERIMENTAL
Intervention: Optimal Drop Height Drop Jump Training (OG)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Higher Drop Height Drop Jump Training (HG)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Weight Training (WG)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Lower Drop Height Drop Jump Training (LG)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 55
Study: 33454216

Group type: EXPERIMENTAL
Intervention: Serum procalcitonin (PCT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: LRINEC score
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (cellulitis)
Number of subjects: 25
Study: 35879728

Group type: EXPERIMENTAL
Intervention: e‐CBT (five sessions)
Number of subjects: 138

Group type: COMPARATOR
Intervention: EDU (online education about surgery and healthy lifestyle)
Number of subjects: 138

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 138
Study: 34684536

Group type: EXPERIMENTAL
Intervention: Privative diet (avoiding meat, gluten, and lactose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control balanced diet (including meat, gluten, and lactose)
Number of subjects: 40
Study: 32844712

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TTh) for 2 years
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo during the first year, followed by Testosterone therapy (TTh) during the second year
Number of subjects: 55
Study: 36151609

Group type: EXPERIMENTAL
Intervention: Health‐Smart Weight Loss (HSWL) Program
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Patient‐Centred Culturally Sensitive Weight Loss Maintenance Program (PCCS‐WLM Program)
Number of subjects: 683

Group type: COMPARATOR
Intervention: Standard Behavioural Weight Loss Maintenance Program (SB‐WLM Program)
Number of subjects: 683
Study: 33691278

Group type: EXPERIMENTAL
Intervention: Banister TRIMP
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lucia TRIMP
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Edwards TRIMP
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Training Stress Score
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Session Rating of Perceived Exertion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Kilojoules
Number of subjects: 9
Study: 33876339

Group type: EXPERIMENTAL
Intervention: Er:YAG laser‐assisted flapless corticotomy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control side (conventional technique)
Number of subjects: 18
Study: 34941558

Group type: EXPERIMENTAL
Intervention: Fixed Anchor (FA)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Adherence to Anchoring Strategy
Number of subjects: 101
Study: 34263641

Group type: EXPERIMENTAL
Intervention: Nomograms for overall survival (OS)
Number of subjects: 6947

Group type: EXPERIMENTAL
Intervention: Nomograms for cancer-specific survival (CSS)
Number of subjects: 6947

Group type: EXPERIMENTAL
Intervention: Nomograms for OS and CSS
Number of subjects: 6947
Study: 33306589

Group type: EXPERIMENTAL
Intervention: Resistance training to failure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Resistance training not to failure
Number of subjects: 12
Study: 32134048

Group type: EXPERIMENTAL
Intervention: Template group (3D printed guide template)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional group (traditional surgical methods)
Number of subjects: 34
Study: 35418412

Group type: EXPERIMENTAL
Intervention: Test-and-treat plus L. reuteri
Number of subjects: 272

Group type: COMPARATOR
Intervention: Test-and-treat plus placebo
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Standard care plus L. reuteri
Number of subjects: 272

Group type: COMPARATOR
Intervention: Standard care plus placebo
Number of subjects: 272
Study: 33554885

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) for 15 sessions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low power laser therapy (LPLT) for 15 sessions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (KT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (LPLT)
Number of subjects: 60
Study: 32114185

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBTI)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Sleep hygiene (SH) attention control condition
Number of subjects: 165
Study: 34542830

Group type: EXPERIMENTAL
Intervention: Galcanezumab (120 mg/month with 240 mg loading dose)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Galcanezumab (120 mg/month)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study: 33109271

Group type: EXPERIMENTAL
Intervention: Group Post‐Admission Cognitive Therapy for Suicidality (GPACTS)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Individual Supportive Therapy (IST)
Number of subjects: 240
Study: 32129815

Group type: EXPERIMENTAL
Intervention: Robot-assisted pancreaticoduodenectomy (RPD)
Number of subjects: 187
Study: 34523807

Group type: COMPARATOR
Intervention: Itepekimab (0.3, 1, 3, or 10 mg/kg infusion or 150 mg subcutaneously)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Itepekimab (75 or 150 mg weekly for 4 weeks subcutaneously)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Itepekimab
Number of subjects: 63
Study: 32348539

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection every 4 weeks (2q4)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection every 8 weeks (2q8)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Macular laser photocoagulation (laser control)
Number of subjects: 107
Study: 34741460

Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia requiring medical assistance
Number of subjects: 9208

Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia requiring any assistance
Number of subjects: 9208

Group type: COMPARATOR
Intervention: No severe hypoglycemia episodes
Number of subjects: 9208
Study: 32539098

Group type: EXPERIMENTAL
Intervention: Telephone support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short message service support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35428349

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 337
Study: 36047018

Group type: EXPERIMENTAL
Intervention: Standard protocol (SP) - comprehensive ultrasound monitoring every clinic visit
Number of subjects: 100

Group type: COMPARATOR
Intervention: Limited protocol (LP) - limited-frequency ultrasound monitoring (only at end of treatment)
Number of subjects: 100
Study: 32422099

Group type: EXPERIMENTAL
Intervention: Intensive and sustained vasodilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 36216003

Group type: EXPERIMENTAL
Intervention: Telemedicine model for abortion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33792800

Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg twice daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Minocycline and Placebo (combined)
Number of subjects: 69
Study: 32202705

Group type: EXPERIMENTAL
Intervention: ASP0113
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 35046508

Group type: COMPARATOR
Intervention: Intravenous placebo (n=54)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Low dose ketamine (0.2 mg/kg; n=53)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Standard dose ketamine (0.5 mg/kg; n=51)
Number of subjects: 158
Study: 33909353

Group type: EXPERIMENTAL
Intervention: Acupuncture as adjunctive therapy
Number of subjects: 0
Study: 32109179

Group type: EXPERIMENTAL
Intervention: Cureit (bioavailable curcumin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35654673

Group type: EXPERIMENTAL
Intervention: Sandblasted zirconium blocks treated with 50μm aluminium oxide particles and bonded with 3M™ Scotchbond™ Universal adhesive
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enamel specimens treated with 37% phosphoric acid and bonded with 3M™ Scotchbond™ Universal adhesive
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated zirconium blocks bonded with 3M™ Scotchbond™ Universal adhesive
Number of subjects: 60
Study: 34655432

Group type: EXPERIMENTAL
Intervention: Cetagliptin 100 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cetagliptin 400 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cetagliptin (various doses 12.5-400 mg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cetagliptin
Number of subjects: 66
Study: 32798835

Group type: EXPERIMENTAL
Intervention: Food-related behavioral activation therapy (F-BA)
Number of subjects: 1025

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 1025
Study: 32827200

Group type: EXPERIMENTAL
Intervention: 12-week exercise programme (1 group session and 3 individual sessions per week)
Number of subjects: 80
Study: 35034803

Group type: EXPERIMENTAL
Intervention: SSIGN score
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Leibovich score
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: AJCC/TNM stage
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: ASSURE score
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: GRANT score
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: UISS score
Number of subjects: 358
Study: 35835626

Group type: EXPERIMENTAL
Intervention: Edible gummies
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Cannabis packages with a helps‐you‐relax health claim
Number of subjects: 841

Group type: COMPARATOR
Intervention: Visual displays of tetrahydrocannabinol content and health warnings
Number of subjects: 841
Study: 33076693

Group type: EXPERIMENTAL
Intervention: LCI
Number of subjects: 1502

Group type: COMPARATOR
Intervention: WLI
Number of subjects: 1502
Study: 32611862

Group type: EXPERIMENTAL
Intervention: Propex Pixi
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Formatron D10
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 90
Study: 35579606

Group type: EXPERIMENTAL
Intervention: Moderate walking exercise (150 minutes weekly, 3 times a week for 12 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vigorous walking exercise (75 minutes weekly, 3 times a week for 12 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 35
Study: 34011237

Group type: EXPERIMENTAL
Intervention: Expressive writing with guidance to promote constructive and discourage unconstructive styles (EP+)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Expressive writing with no guidance (EP)
Number of subjects: 151
Study: 33275766

Group type: EXPERIMENTAL
Intervention: Pacritinib
Number of subjects: 536

Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 536
Study: 33950516

Group type: EXPERIMENTAL
Intervention: EEG findings in delirious patients (burst-suppression)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: EEG findings in delirious patients (rhythmic/periodic patterns)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: EEG findings in delirious patients (epileptiform activity)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Presence of at least one abnormal EEG finding
Number of subjects: 91
Study: 36427269

Group type: EXPERIMENTAL
Intervention: Booklet for knowledge and prevention of HIV mother-to-child transmission
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual service care
Number of subjects: 45
Study: 33221891

Group type: EXPERIMENTAL
Intervention: Genetically predicted leptin level
Number of subjects: 50508

Group type: EXPERIMENTAL
Intervention: Genetically predicted adiponectin level
Number of subjects: 50508

Group type: EXPERIMENTAL
Intervention: Genetically predicted resistin level
Number of subjects: 50508

Group type: EXPERIMENTAL
Intervention: Genetically predicted chemerin and retinol-blinding protein 4 levels
Number of subjects: 50508
Study: 32541295

Group type: EXPERIMENTAL
Intervention: Fellowship-trained minimally invasive gynecologic surgery subspecialists (n=19)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Minimally invasive gynecologic surgery graduating or recently graduated fellows (n=16)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Specialists in obstetrics and gynecology (n=15)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Graduating or recently graduated residents (n=18)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Residents, fellows, and specialists in obstetrics and gynecology
Number of subjects: 68
Study: 36129240

Group type: EXPERIMENTAL
Intervention: TAT patch
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham patch
Number of subjects: 16
Study: 32381188

Group type: EXPERIMENTAL
Intervention: Active side branch protection (SB-P) strategy (elective 2-stent strategy for large SBs and jailed balloon technique for small SBs)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Conventional strategy (provisional stenting for large SBs and jailed wire technique for small SBs)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Jailed balloon technique for small SBs
Number of subjects: 335

Group type: COMPARATOR
Intervention: Jailed wire technique for small SBs
Number of subjects: 335
Study: 34447995

Group type: EXPERIMENTAL
Intervention: Early rhythm control therapy in asymptomatic patients (395/801)
Number of subjects: 2633

Group type: COMPARATOR
Intervention: Usual care in symptomatic patients (406 patients)
Number of subjects: 2633

Group type: EXPERIMENTAL
Intervention: Early rhythm control therapy in symptomatic patients
Number of subjects: 2633

Group type: EXPERIMENTAL
Intervention: Change in symptom status at 24 months follow-up
Number of subjects: 2633
Study: 34215703

Group type: EXPERIMENTAL
Intervention: belimumab 10 mg/kg every 28 days for ?7 years
Number of subjects: 142
Study: 32867741

Group type: EXPERIMENTAL
Intervention: Occupational health check-ups
Number of subjects: 23220

Group type: EXPERIMENTAL
Intervention: Physician's advice to change health behavior
Number of subjects: 23220

Group type: EXPERIMENTAL
Intervention: Participation in health promotion programs
Number of subjects: 23220

Group type: COMPARATOR
Intervention: Asthmatic workers
Number of subjects: 23220

Group type: COMPARATOR
Intervention: Non-asthmatic workers
Number of subjects: 23220
Study: 34957386

Group type: EXPERIMENTAL
Intervention: Neuropsychological rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 35304924

Group type: EXPERIMENTAL
Intervention: adamgammadex 2 mg.kg-1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: adamgammadex 4 mg.kg-1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: adamgammadex 6 mg.kg-1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: adamgammadex 8 mg.kg-1
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study: 35475258

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Tocilizumab and Placebo
Number of subjects: 452
Study: 33359562

Group type: EXPERIMENTAL
Intervention: Colistin sulfate plus neomycin sulfate for 14 days (DT group)
Number of subjects: 105

Group type: COMPARATOR
Intervention: No treatment (NDT group)
Number of subjects: 105
Study: 34533507

Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional nursing care alone
Number of subjects: 40
Study: 35875789

Group type: EXPERIMENTAL
Intervention: Peripheral repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 65
Study: 32376544

Group type: EXPERIMENTAL
Intervention: Peripheral blood albumin (Hb) level
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Increase of Hb levels by 1 standard deviation
Number of subjects: 419

Group type: COMPARATOR
Intervention: Comparison between S0 group and the 3 arteriosclerosis groups
Number of subjects: 419
Study: 35134489

Group type: EXPERIMENTAL
Intervention: Henna mouthwash (2% aqueous extract, prescribed twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate 0.2% mouthwash (prescribed twice daily)
Number of subjects: 40
Study: 34106948

Group type: EXPERIMENTAL
Intervention: Good menstrual hygiene practices
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Age range 16-19 years
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: School grade level 10
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Maternal education (primary)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Maternal education (secondary)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Maternal education (college)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Having regular menses
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Good knowledge regarding menstruation
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Discussing menstrual hygiene with friends
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Obtaining money for pads from the family
Number of subjects: 546
Study: 33464113

Group type: EXPERIMENTAL
Intervention: Cooperative framing
Number of subjects: 182

Group type: COMPARATOR
Intervention: Competitive framing
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Simultaneous behaviors (within the same 10-s interval)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Lagged effects
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Personality traits
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Situational context
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Participants' individual complementarity coefficients
Number of subjects: 182
Study: 35026987

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (various pre/post-partum dose combinations)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1060